

CDDF – SITC JOINT MEETING

THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE



cancer cell © vitanovski



MARCH 19-21, 2018



MERCURE HOTEL MOA BERLIN
BERLIN, GERMANY



www.itoc-conference.eu



PROGRAMME



6TH IMMUNOTHERAPY
OF CANCER CONFERENCE

THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

 APRIL 12-14, 2019  VIENNA, AUSTRIA



The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) have the great pleasure to invite you to take part in the 6th Immunotherapy of Cancer Conference (ITOC6) – the leading European conference providing a global platform for translational research in the field of immuno-oncology.

The ITOC series of conferences is the premier meeting in Europe for scientific exchange, networking and education within the cancer immunotherapy field.

6TH EDITION
APRIL 12-14, 2019
VIENNA, AUSTRIA

SAVE THE DATE

The programme will focus on the latest challenges of translational research with a special emphasis on innovations in combination therapy, immuno-monitoring and biomarker development.

www.itoc-conference.eu

TABLE OF CONTENTS

WELCOME LETTER	PAGE 4
CANCER DRUG DEVELOPMENT FORUM & ORGANIZING PARTNERS	PAGE 5
ITOC5 POSTER PRIZE	PAGE 5
CONFERENCE COMMITTEE	PAGE 6
ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)	PAGE 6
PROGRAMME AT A GLANCE	PAGE 7
SCIENTIFIC PROGRAMME	PAGE 8
POSTER PRESENTATIONS	PAGE 11
FLOORPLAN	PAGE 17
SPONSORS, EXHIBITORS, PARTNERS	PAGE 18
GENERAL INFORMATION	PAGE 23



This is an ESO recommended event.



WELCOME LETTER

Welcome to the fifth edition of the Immunotherapy of Cancer Conference (ITOC5), the premier meeting for education, scientific exchange and networking within cancer immunotherapy.

This meeting has been growing rapidly into a global platform for translational research in the field of immuno-oncology.

The scientific programme with an international faculty will focus on many topics such as Immune Escape, Emerging concepts/novel agents, Oncolytic Viruses, Anti-cancer vaccines, Combination Therapy, Cell therapy, Immuno-monitoring, Microbiome in Immunotherapy.

Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development and in cooperation with the Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC5 in the beautiful city of Berlin.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the online survey after the conference and please do not hesitate to reach out to our team on site or via email (itoc@medacad.org)

Yours sincerely,

Prof. Dr. Ulrich Keilholz
Conference President

Prof. Dr. Lisa Butterfield
Conference President

Prof. Dr. Volkmar Nüssler
Munich Tumour Center

Prof. Dr. Heinz Zwiernia
Scientific Chairman



CANCER DRUG DEVELOPMENT FORUM



The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA's focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation's breadth of interests and activities.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF's list of publications at: www.cddf.org.

THIS PROGRAM IS PRESENTED IN COLLABORATION WITH



Society for Immunotherapy of Cancer



ITOC5 POSTER PRIZE



We are proud to announce the ITOC 5 Poster Prize which will be awarded at the 5th Immunotherapy of Cancer Conference thanks to the generous support of the Tumor Center Munich.

Prizes will be awarded to the three best poster presentations. The winners will receive a certificate and a prize of EUR 1000,-/700,-/500,-.

Winners are selected by the scientific committee according to the following criteria:

- Scientific content/methodology
- Novelty and originality of research
- Ability of the author to present the poster in a concise and clear manner and to answer questions during the dedicated poster sessions.

Poster reviewing-Committee:

- Chairman: Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Leisha Ann Emens (Johns Hopkins Medicine Baltimore, United States)
- Ulrich Keilholz (Charité Comprehensive Cancer Center, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)

CONFERENCE COMMITTEE

CONFERENCE PRESIDENTS

- Lisa Butterfield (University of Pittsburgh, United States)
- Ulrich Keilholz (Charité Comprehensive Cancer Center, Germany)

CHAIRMAN OF THE SCIENTIFIC COMMITTEE

- Heinz Zwierzina (Innsbruck University, Austria)

SCIENTIFIC COMMITTEE

- Paolo Ascierto (Istituto Nazionale Tumori, Italy)
- Leisha Ann Emens (Johns Hopkins Medicine Baltimore, United States)
- John Haanen (Netherlands Cancer Institute, The Netherlands)
- Leif Hakansson (Universitetssjukhuset Linköping, Sweden)
- Robert F. Hawkins (The Christie Hospital, United Kingdom)
- Howard L. Kaufman (Replimune Group Inc., United States)
- Samir N. Khleif (Georgia Regents University, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, USA)
- Michael May (Bristol-Myers-Squibb, Germany)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Jose Saro (Roche, Switzerland)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Kira Pharmaceuticals, USA)
- Rolf Stahel (University Hospital Zurich, Switzerland)
- Zhen Su (Merck KGaA, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)



The 5th ImmunoTherapy of Cancer Conference, Prague, Czech Republic (March 19 – 21, 2018) has been granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants who attend the above mentioned activity to validate their credits in their own country.



PROGRAMME AT A GLANCE

MONDAY, MARCH 19, 2018

09.00	Registration Opens
11.00 – 11.10	Welcome Address
11.10 – 11.40	Opening Lecture
11.40 – 13.10	Opening Plenary Symposium 1: Overcoming Immune Escape
13.10 – 14.00	Lunch
14.00 – 15.50	Plenary Symposium 2: Emerging concepts / novel agents (1) NEW: Hot Topic Interactive Experts' Session: Impact of the Microbiome in Immunotherapy
15.50 – 16.20	Coffee Break
16.20 – 18.20	Plenary Symposium 2: Emerging concepts / novel agents (2)
18.20	Welcome Reception and Poster Viewing

TUESDAY, MARCH 20, 2018

08.30 – 10.30	Plenary Symposium 3: Oncolytic Viruses & Innate Immunity NEW: Hot Topic Interactive Experts' Session: Oncolytic Viruses
10.30 – 11.00	Coffee Break
11.00 – 12.35	Plenary Symposium 4: Anti-cancer vaccines
12.35 – 14.00	Lunch
14.00 – 15.00	NEW: Hot Topic Interactive Experts' Session: Combinations to target immune excluded and immune desert solid Tumours
15.00-15.45	Lifetime Award - Carl June
15.45 – 16.15	Coffee Break
16.15 – 17.25	Plenary Symposium 5: Cell therapy
17.25 – 18.25	Plenary Session 6 - Young Researcher Session
18.25 – 19.30	Poster Viewing with Presenters
20.00 – 23.00	ITOC5 Conference Dinner

WEDNESDAY, MARCH 21, 2018

08.30 – 10.30	Plenary Symposium 7: Monitoring of Immune response
10.30 – 11.00	Coffee Break
11.00 – 12.00	Plenary Symposium 8: Clinical Breakthrough with Immunotherapy Joint Session with ESMO
12.00 – 12.30	Best Poster Awards & Closing Remarks
12.30 – 13.30	Lunch

SCIENTIFIC PROGRAMME

MONDAY, MARCH 19, 2018

09.00

Registration Opens

11.00 – 11.10

Welcome Address

Heinz Zwierzina, Innsbruck, Austria

11.10 – 11.40

Impact of translational research on current immunotherapy trial programs

Ulrich Keilholz, Berlin, Germany

11.40 – 13.10

Opening

Plenary Symposium 1: Overcoming Immune Escape

Chair: Lisa Butterfield, Ulrich Keilholz

11.40 – 12.10

Tumor/Immune cell metabolism

Ping-Chih Ho, Lausanne, Switzerland

12.10 – 12.40

Current understanding of resistance to immunotherapy

Samir Khleif, Augusta, GA, USA

12.40 – 13.10

Novel genomics tools for cancer immunotherapy

Jacques Banchereau, Bar Harbor, ME, USA

13.10 – 14.00

Lunch

14.00 – 15.50

Plenary Symposium 2: Emerging concepts / novel agents (1)

Chair: Samir Khleif, John Haanen

14.00 – 15.00

NEW: Hot Topic Interactive Experts' Session: Impact of the Microbiome in Immunotherapy

The impact of the microbiome on anti-tumor immunity and immunotherapy

Andreas Diefenbach, Berlin, Germany

The role of the Microbiome for cancer therapy

TBC

15.00 – 15.25

STING activation sequenced with immune checkpoint modulators overcomes immune tolerance

Leisha Emens, Baltimore, MD, USA

15.25 – 15.50

IDO inhibition in combination with checkpoint inhibition

Jason Luke, Chicago, IL, USA

15.50 – 16.20

Coffee Break

16.20 – 18.20

Plenary Symposium 2: Emerging concepts / novel agents (2)

Chair: Paolo Ascierto, Sebastian Kobold

16.20 – 16.45

Combination of anti-LAG 3 antibodies with other checkpoint inhibitors

Paolo Ascierto, Naples, Italy

16.45 – 17.10

TLR and checkpoint inhibitor mediated immune modulation in tumor draining lymph nodes

Tanja de Gruijl, Amsterdam, Netherlands

17.10 – 17.35

Platelets, GARP and Cancer Immunotherapy

Zihai Li, Charleston, SC, USA

17.35 – 17.50

Immune landscape analysis to identify targets for immunotherapy across human carcinomas A1

J. Schnappinger¹, T. Straub², S. Lee³, T. Schiergens³, R. Oberneder⁴, E. Nöbner¹; ¹Immunoanalytics, Helmholtz Center, Munich, Germany, ²Biomedical Center, Molecular Biology, Munich, Germany, ³Biobank under the administration of the Human Tissue and Cell Research Foundation, Department of General, Visceral and Transplantation Surgery, Hospital of the LMU, Munich, Germany, ⁴Urological Clinic Munich-Planegg, Munich, Germany.

17.50 – 18.05

Circulating regulatory T-cells and the clinical outcome of VEGF-targeted treatment of metastatic colorectal cancer patients: focused on KRAS status and primary tumour sidedness A2

L. Zdravilova-Dubská¹, E. Budinska², B. Bencsikova¹, K. Pilatova¹, R. Obermannova¹, R. Nenutil¹, D. Valík¹; ¹Masaryk Memorial Cancer Institute, Brno, Czech Republic, ²Masaryk University, Brno, Czech Republic.

18.05 – 18.20

The use of EGFR-CD3 bispecific antibody and antigen-specific high avidity T cells to target cancer associated fibroblasts and cancer cells within a melanoma organoid system A3

N. Reddy, B. Chung, E. Chu, A. Esmaeili, T. Tu, P. Lee; City of Hope National Cancer Center, Duarte, CA, United States.

18.20

Welcome Reception and Poster Viewing

TUESDAY, MARCH 20, 2018

08.30 – 10.30

Plenary Symposium 3: Oncolytic Viruses & Innate Immunity

Chair: Leif Hakansson, Eric Tartour

08.30 – 09.30

NEW: Hot Topic Interactive Experts' Session: Oncolytic Viruses

Michael Bergmann, Vienna, Austria

Cancer gene therapy: design of T-SIGn oncolytic viruses to deliver localized combination immunotherapy within the tumor microenvironment

Brian Champion, Oxfordshire, United Kingdom

Engineering Vaccinia Virus for Intratumoral Delivery to Generate "In Situ Vaccination" against Cancer

Liang Deng, New York, NY, United States

09.30 – 09.50

Reprogramming macrophages for tumour immunity

Michele de Palma, Lausanne, Switzerland

09.50 – 10.10

Next generation immunotherapies: NK cells and other targets

Stéphanie Cornen, Marseille, France

10.10 – 10.30

PD-1 expression on innate lymphoid cells

Shoba Amarnath, Newcastle Upon Tyne, United Kingdom

10.30 – 11.00

Coffee Break

11.00 – 12.35

Plenary Symposium 4: Anti-cancer vaccines

Chair: Barbara Seliger, Lei Zheng

11.00 – 11.20

Tumor antigen-specific T cell epitopes - identification and clinical application

Stefan Eichmueller, Heidelberg, Germany

11.20 – 11.40

Mass spectrometry-verified target epitopes for therapeutic cancer vaccine design

Angelika Riemer, Heidelberg, Germany

11.40 – 12.00

Development of DC vaccines and combinations

Lisa Butterfield, Pittsburgh, PA, USA

12.00 – 12.20

Combination therapy with anti-cancer vaccines and checkpoint Inhibitors

Lei Zheng, Baltimore, MD, USA

12.20 – 12.35

The adjuvant effect of melanin is superior to Incomplete Freund adjuvant in a tumor subunit vaccine model **A4**

A. F. Carpentier¹, T. Tran², F. Sejalon¹, F. Geinguenaud³, E. Tartour⁴, L. Motte⁵, C. Banissi¹; ¹Hopital Saint Louis, AP/HP, Paris, France, ²Inserm U970, Paris, France, ³Cnrs umr 7244, Bobigny, France, ⁴Inserm U970, Paris, France, ⁵Cnrs umr 7244, Bobigny, France.

12.35 – 14.00

Lunch

14.00 – 15.00

NEW: Hot Topic Interactive Experts' Session: Combinations to target immune excluded and immune desert solid Tumours

Please see page 22 for details

15.00-15.45

Presentation of the ITOC Lifetime Award by Heinz Zwierzina

CAR T cells in haematological malignancies: focused on the cure

Carl June, Philadelphia, PA, USA

15.45 – 16.15

Coffee Break

16.15 – 17.25

Plenary Symposium 5: Cell therapy

Chair: Robert Hawkins, Zihai Li

16.15 – 16.35

Adoptive T cell therapy of glioblastoma

Bryan Choi, Boston, MA, USA

16.35 – 17.00

Arming T cells with C-X-C Motive Receptor 6 as a universal approach for tumor directed T cell recruitment

Sebastian Kobold, Munich, Germany

17.00 – 17.25

Personalized Whole Tumour Antigen Vaccines in Ovarian Cancer: Using Tumors for Therapy

Lana Kandalaft, Lausanne, Switzerland

17.25 – 18.25

Plenary Session 6 - Young Researcher Session

Chair: Leisha Emens, Sebastian Kobold

17.25 – 17.40

Omental fat in ovarian cancer induces metabolic and immune alterations **A5**

M. Suarez-Carmona¹, N. A. Valous², M. Hampel¹, B. M. Lenoir¹, S. Schott³, S. Eismann³, I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹National Center for Tumor Diseases (NCT), Heidelberg, Germany, ²Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany, ³Department of Obstetrics & Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

17.40 – 17.55

GARP-TGFβ Axis on Activated Platelets Supports Tumor Progression **A6**

A. Metelli, B. Riesenberger, B. Wu, C. Wallace, S. Sun, B. Liu, Z. Li; Medical University of South Carolina, Charleston, SC, United States.

17.55 – 18.10

Preclinical characterization of a PD-1-CD28 fusion receptor in CD4+ T cells for T cell-based immunotherapy of pancreatic cancer and Non-Hodgkin Lymphoma (A7)

F. Rataj, F. Kraus, S. Grassmann, Michael Chaloupka, Justyna Ogonek, Jin Zhang, Svenja Rausch, Stefan Endres and Sebastian Kobold; Ludwig-Maximilian-University, München, Germany.

18.10 – 18.25

Breast cancer immunotherapy using magnetised oncolytic viruses (A8)

H. AL-Janabi¹, J. Conner², Z. Taher¹, S. Staniland¹, M. Muthana¹; ¹The University of Sheffield, Sheffield, United Kingdom, ²Virtu Biologics, Glasgow, United Kingdom.

18.25 – 19.30

Poster Viewing with Presenters

20.00 – 23.00

ITOC5 Conference Dinner

WEDNESDAY, MARCH 21, 2018

08.30 – 10.30

Plenary Symposium 7: Monitoring of Immune response

Chair: Marco Gerlinger, Luis Paz-Ares

08.30 – 08.50

Detection of tumour-infiltration immune cells by PET

Secondo Lastoria, Naples, Italy

08.50 – 09.10

Tissue biomarkers of response to immunotherapy

Julien Adam, Villejuif, France

09.10 – 09.35

Tumor mutational burden as a predictive biomarker

Solange Peters, Lausanne, Switzerland

09.35 – 09.55

Circulating tumor DNA and response to immunotherapy

Marco Gerlinger, London, United Kingdom

09.55 – 10.10

Determining tumor mutation load using an NGS-based, target gene panel **A9**

J. C. Machado¹, J. Reis¹, M. Fernandes², R. Silva¹, L. Cirnes¹, R. Chaudhary³, F. Carneiro⁴, J. L. Costa¹; ¹IPATIMUP, Porto, Portugal, ²Centro Hospitalar de São João, Porto, Portugal, ³Thermo Fisher Scientific, Carlsbad, CA, United States, ⁴Faculty of Medicine, Porto, Portugal.

10.10 – 10.30

Resident memory CD8+T cells as a biomarker of response to immunotherapy

Eric Tartour, Paris, France

10.30 – 11.00

Coffee Break

11.00 – 12.00

Plenary Symposium 8: Clinical Breakthrough with Immunotherapy

Joint Session with ESMO

Chair: Christoph Zielinski, Heinz Zwierzina

11.00 – 11.20

Adjuvant Therapy of Melanoma – Current Data and EORTC perspective

Ulrich Keilholz, Berlin, Germany

11.20 – 11.40

Lung Cancer

Luis Paz-Ares, Madrid, Spain

11.40 – 12.00

Renal cell carcinoma

Giuseppe Procopio, Milan, Italy

12.00 – 12.30

Best Poster Awards & Closing Remarks

12.30 – 13.30

Lunch

POSTER PRESENTATIONS

POSTER SESSION P01.

Preclinical models

P01.01 Orthotopic HCC Mouse Models to Predict Response to Immuno therapy

C. Hage¹, S. Hoves¹, M. Ashoff¹, L. Strauss¹, M. Perro², F. Herting¹, F. Kiessling³, T. Pöschinger¹; ¹Roche Innovation Center Munich, Penzberg, Germany, ²Roche Innovation Center Zurich, Zurich, Switzerland, ³RWTH Aachen University, Aachen, Germany.

P01.02 A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models

B. Volz¹, K. Kapp¹, D. Oswald¹, B. Wittig², M. Schmidt¹; ¹Mologen AG, Berlin, Germany, ²Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin, Germany.

P01.03 Building Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse allograft tumor model for efficacy evaluation of combinatory immunotherapie

Y. Song, B. Liu, A. Xiaoyu An, L. Zhang, J. Cai, Q. Shi, H. Qixiang Li, D. Xuesong Ouyang; Crown Bioscience, San Diego, CA, United States.

P01.04 Preclinical development of a therapeutic antibody for the treatment of epithelial ovarian carcinoma

M. Suarez-Carmona¹, D. S. Ferber¹, F. Momburg², M. Meyer², M. Hampel¹, B. M. Lenoir¹, S. Schott³, I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹National Center for Tumor Diseases (NCT), Heidelberg, Germany, ²Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany, ³Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

P01.05 A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant

C. S. Ozverel¹, I. Karaboz¹, A. Nalbantsoy²; ¹Biology Department, Faculty of Science, Ege University, Izmir, Turkey, ²Bioengineering Department, Faculty of Engineering, Ege University, Izmir, Turkey.

P01.06 Human tissue explant cultures from ovarian carcinoma resectates: an innovative, high-predictive link between basic research and clinical trial

M. Hampel¹, A. Heinzelmann¹, M. Suarez-Carmona¹, U. Prüfer¹, S. Schott², S. Eismann², I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹National Center for Tumor Diseases, Heidelberg, Germany, ²Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

POSTER SESSION P02.

Tumor Immunity and Microenvironment

P02.01 Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab

C. Jensen^{1,2}, D. Madsen³, M. Hansen³, H. Schmidt⁴, I. Svane³, M. Karsdal¹, N. Willumsen¹; ¹Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ²Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark, ³Center for Cancer Immune Therapy, Department of Haematology and Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark, ⁴Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

P02.02 Humanized Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immuno-Oncology Therapies

T. E. Kähkönen¹, M. I. Suominen¹, J. M. Halleen¹, T. Haapaniemi², A. Tanaka³, M. Seiler³, J. Bernoulli¹; ¹Pharmatest Services, Turku, Finland, ²BioSiteHisto Ltd, Tampere, Finland, ³Taconic Biosciences, Hudson, NY, United States.

P02.03 Cancer cells regulate Interleukin-22 production to promote tumor growth

C. Voigt¹, P. May¹, A. Gottschlich¹, A. Markota¹, D. Wenk¹, I. Gerlach¹, J. Suárez Gosálvez¹, T. Ruzicka¹, A. Kraechan¹, S. Voigt², G. Stathopoulos^{3,4}, K. Arendt³, C. Heise¹, F. Rataj¹, K. Janssen⁵, M. Königshoff⁶, H. Winter⁶, I. Himsel², W. Thasler², M. Schnurr¹, S. Rothenfußer¹, S. Endres¹, S. Kobold¹; ¹Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany, ²Brustzentrum Klinikum Dritter Orden, Munich, Germany, ³Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, Munich, Germany, ⁴Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, University of Patras, Rio, Greece, ⁵Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany, ⁶Department of Thoracic Surgery, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

P02.04 Omental fat in ovarian cancer induces lymphangiogenesis

D. Ferber^{*1}, B. Lenoir^{*1}, M. Suarez-Carmona¹, S. Schott², I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹National Center for Tumor Diseases, Heidelberg, Germany, ²Heidelberg University Hospital, Heidelberg, Germany.

P02.05 Spatial profiling and functional phenotyping of mast cell distribution in human cancer tissues

D. Ferber¹, M. Suarez-Carmona¹, J. N. Kather¹, B. Lenoir¹, M. Hampel¹, U. Prüfer¹, S. Eismann², S. Schott², I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany, ²Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

P02.06 Digital spatial profiling platform allows for spatially- resolved, multiplexed measurement of solid tumor protein distribution and abundance in FFPE tissue sections

A. Winfield; Nanostring, Seattle, WA, United States.

P02.07 In vitro Culture of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy in Breast Cancer Patients

s. seber^{1,2}, t. yetisyigit^{1,2}, b. turgut^{3,2}, S. Bulus^{4,5}, S. Ozkan Gürdal^{6,2}, M. Oznur^{7,2}; ¹Medical Oncology Department, Tekirdag, Turkey, ²Namik Kemal University Hospital, Tekirdag, Turkey, ³Hematology Department, Tekirdag, Turkey, ⁴Hematology Laboratory, Tekirdag, Turkey, ⁵Namik Kemal University Hospital, Tekirdag, Turkey, ⁶General Surgery Department, Tekirdag, Turkey, ⁷Pathology Department, Tekirdag, Turkey.

P02.08 The role of myeloid-derived suppressor cells in autologous hematopoietic stem cell transplantation

A. Betsch¹, O. Rutgeerts¹, S. Fevery¹, B. Sprangers², D. Dierickx², M. Beckers²; ¹KU Leuven, Leuven, Belgium, ²UZ Leuven, Leuven, Belgium.

P02.09 Standard normoxic versus physiological hypoxic culture of AML patients'(pts)whole blood(WB) samples with immunomodulatory Kits yields comparable proportions of Dendritic cells and functional results

F. Doraneh gard¹, D. Amberger¹, M. Weinmann¹, C. Boeck¹, C. Gunsilius¹, C. Kugler¹, J. Werner², A. Kraemer³, A. Rank⁴, C. Schmid⁴, H. Schmetzer¹; ¹University Hospital of LMU, Department for Hematopoietic cell Transplantations, Med³, munich, Germany, ²University Hospital of Tuebingen, Department for Hematology and Oncology, Tuebingen, Germany, ³University Hospital of Oldenburg, Department for Hematology and Oncology, Oldenburg, Germany, ⁴Municipal Hospital of Augsburg, Department of Hematology and Oncology, Augsburg, Germany.

P02.10 Insights into the tumor microenvironment and human TRBV gene polymorphism revealed by long-amplicon immune repertoire sequencing

G. M. Lowman¹, T. Looney², A. Glavin², E. Linch¹, L. Miller¹, D. Topacio-Hall¹, S. Pabla³, S. Glenn³, A. Pankov², J. Zheng², R. Hartberg⁴, H. Almåsba⁴, T. E. Stav-Noraas⁴, A. Kullmann⁴, J. Conroy³, C. Morrison³, F. Hyland², M. Andersen¹; ¹Thermo Fisher Scientific, Carlsbad, CA, United States, ²Thermo Fisher Scientific, South San Francisco, CA, United States, ³OmniSeq, Inc., Buffalo, NY, United States, ⁴Thermo Fisher Scientific, Oslo, Norway.

P02.11 Tumor-specific neoantigens drive T-cell clonotype convergence

J. C. Machado¹, J. Reis¹, M. Fernandes², R. Silva¹, L. Cirnes¹, F. Carneiro³, J. L. Costa¹; ¹IPATIMUP, Porto, Portugal, ²Centro Hospitalar de São João, Porto, Portugal, ³Faculty of Medicine, Porto, Portugal.

P02.12 Solubleimmune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients

G. Gamberith^{1,2}, H. Hackl³, P. Wallinger^{1,2}, L. Fandel^{1,2}, J. Kern², F. Augustin⁴, E. Lorenz^{1,2}, E. Hoflehner^{1,2}, F. Mildner^{1,2}, P. Moser⁵, S. Sprung⁶, B. Zelger⁴, S. Köck^{1,2}, A. Amann^{1,2}, G. Schäfer⁴, D. Öfner⁴, H. Maier⁴, Z. Trajanoski³, H. Zwierzina^{1,2}, S. Soppe^{1,2}; ¹Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, ²Tyrolean Cancer Research Institute, Innsbruck, Austria, ³Medical University of Innsbruck, Biocenter, Division of Bioinformatics, Innsbruck, Austria, ⁴Medical University of Innsbruck, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck, Austria, ⁵LKH Innsbruck, Institute of Pathology, Innsbruck, Austria, ⁶Medical University of Innsbruck, Department of Pathology, Innsbruck, Austria.

P02.13 The influence of stromal cells on CD3+CD8+ tumorinfiltrating lymphocyte subpopulations in cancer microtissues

S. Koeck^{1,2}, M. Zwierzina³, G. Gamberith^{1,2}, E. Lorenz^{1,2}, H. Zwierzina^{1,2}, J. Kern^{1,2}, A. Amann^{1,2}; ¹Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, ²Tyrolean Cancer Research Institute, Innsbruck, Austria, ³Medical University of Innsbruck, Department of Plastic, Reconstructive and Aesthetic Surgery, Innsbruck, Austria.

POSTER SESSION P03.

Primary and Acquired Resistance mechanisms

P03.01 The role of Topoisomerasell-α (TOPO IIA) as apredictivefactorfor response to neoadjuvant anthracyclines based chemotherapy in locally advancedbreast cancer

M. M. Gamea; Aswan University, Tanta, Egypt.

P03.02 MiRNA set dysregulation in breast cancer cells can contribute to both primary and acquired resistance to immune checkpoint blockade

A. Halytskiy; Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, Ukraine.

POSTER SESSION P04.

Therapeutic modulation of immune checkpoints

P04.01 Complete clinical remission of stage IV breast cancer with liver, lung, bone and lymph node metastasis combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia and metronomic low-dose chemotherapy

R. Kleef; Ralf Kleef Immunology & Integrative Oncology, Vienna, Austria.

P04.02 Local oncothermia (modulated-electrohyperthermia) against systemic malignancy

A. Szasz, N. Meggyeshazi, E. Borbenyi, R. Mohacsi, T. Garay, P. Torgyik, M. V. Dank; Semmelweis Univeristy, Budapest, Hungary.

P04.03 AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/ adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors

U. Schindler, A. Becker, K. Lawson, L. Jin, J. Jeffrey, J. Kalisiak, F. Yin, K. Zhang, A. Chen, D. Swinarski, M. J. Walters, S. Young, J. P. Powers, J. Tan; Arcus Biosciences, Hayward, CA, United States.

P04.04 AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy

U. Schindler, L. Seitz, D. Ashok, D. Piovesan, J. Tan, D. DiRenzo, F. Yin, M. Leleti, B. Rosen, D. Miles, L. Jin, T. Park, S. Young, F. Soriano, A. Rieger, J. Karakunnel, E. Sharif, J. P. Powers, M. J. Walters; Arcus Biosciences, Hayward, CA, United States.

P04.05 Immune Modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinically approved Response Modifiers improves clinical status, bloodcellregeneration and gives rise to leukemiaspecific adaptive and innate immune reactive cells

C. Schmid¹, M. Atzler², A. Rank³, M. Inngjerdigen⁴, A. Rabe², D. Deen², R. Wang², B. Eiz-Vesper⁵, H. Schmetzer⁶; ¹Dept Med II, Hematopoietic stem cell transplantation, Augsburg University, ⁸⁶¹⁵⁶ Augsburg, Germany, ²Hematopoietic Cell Transplantation Unit, Dept of Med³, ⁸¹³⁷⁷ Munich, Germany, ³Dept of MedII, Section of Hematopoietic Cell Transplantations, University of Augsburg, ⁸⁶¹⁵⁶ Augsburg, Germany, ⁴Dept Immunology, Oslo University Rikshospitalet, ⁰⁰²⁷ Oslo, Norway, ⁵Institute for Transfusion-Medicine, Hannover Medical School, ³⁰⁶²⁵ Hannover, Germany, ⁶Hematopoietic Cell Transplantation Unit, Dept of Med³, University Hospital of Munich, ⁸¹³⁷⁷ Munich, Germany.

POSTER SESSION P05.

Combination therapy

P05.01 Engineering high affinity, soluble T cell receptors for the treatment of cancer

L. Holt, N. Liddy, G. Bossi, J. Harper, J. Dukes, S. Paston, T. Mahon, P. Molloy, M. Sami, E. Baston, B. Cameron, A. Powesland, A. Johnson, N. Hassan, A. Vuidepot, C. Coughlin, B. Jakobsen; Immunocore Ltd, Abingdon, United Kingdom.

P05.02 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for cancer immunotherapy

S. Hamm, T. H. Wulff, K. Kronthaler, S. Schrepfer, U. Parnitzke, A. H. Bretz; ⁴SC AG, Planegg-Martinsried, Germany.

P05.03 Peritumoral gene electrotransfer of interleukin-12 as an adjuvant immunotherapy to intratumoral electrochemotherapy for murine melanoma treatment

K. Ursic¹, S. Kos¹, U. Kamensek¹, M. Cemazar^{1,2}, G. Sersa^{1,3}; ¹Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, Slovenia, ²University of Primorska, Faculty of Health Sciences, Izola, Slovenia, ³University of Ljubljana, Faculty of Health Sciences, Ljubljana, Slovenia.

P05.04 P-MAPA immunotherapy and interleukin-12 on ovarian carcinoma SKOV-3 cells: assessment of the TLR signaling and cytokine/chemokine profile.

L. Chuffa, L. Lupi, M. Cuciello, F. Martinez, F. Delella, W. Fávaro; Institute of Bioscience of Botucatu, Botucatu, Brazil.

P05.05 Impact of natural substances on the efficacy of immunotherapy

M. Luzbetak, N. Süßenguth, B. Mayer; AVT Surgery, Klinikum Großhadern, Munich, Germany.

POSTER SESSION P06.

Anti-cancer vaccines

P06.01 Novel PAP-derived vaccine for the treatment of advanced prostate cancer

P. Le Vu¹, J. Vadakekolathu¹, H. Nicholls¹, D. Christensen², L. Durrant³, A. Pockley⁴, S. E. McArdle¹; ¹The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom, ²Statens Institut, Copenhagen, Denmark, ³Clinical Oncology, Nottingham University, Nottingham, United Kingdom, ⁴The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.

P06.02 HAGE-derived peptide as a vaccine to prevent relapse in TNBC patients: Proof of concepts

D. Nagarajan¹, L. Durrant², G. Pockley¹, S. McArdle¹; ¹NTU, Nottingham, United Kingdom, ²Scancell Holding plc, Nottingham, United Kingdom.

P06.03 Eliciting protective T cell immunity against EBV-associated malignancies by vaccination

J. Rühl¹, C. Citterio¹, C. Leung², C. Münz¹; ¹Institute of Experimental Immunology, Zürich, Switzerland, ²Department of Hematology, University College London Cancer Institute, London, United Kingdom.

POSTER SESSION P07.

Adoptive cell therapy

P07.01 Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors

C. Karches¹, M. Benmehbarek¹, M. Schmidbauer¹, M. Kurzay¹, R. Klaus¹, M. Geiger², S. Lesch¹, B. Cadilha¹, F. Rataj¹, C. Heise¹, R. Murr², J. vom Berg³, M. Jastroch⁴, D. Lamp⁴, P. Döwett¹, G. Niederfellner⁵, C. Sustmann⁵, S. Endres¹, C. Klein², S. Kobold¹; ¹Division of Clinical Pharmacology, München, Germany, ²Roche Innovation Center Zurich, Schlieren, Switzerland, ³Institute of Laboratory Animal Science, Zurich, Switzerland, ⁴Helmholtz Diabetes Center and German Diabetes Center (DZD), München, Germany, ⁵Roche Innovation Center Munich, Penzberg, Germany.

P07.02 Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

M. Benmehbarek¹, C. Karches¹, M. Schmidbauer¹, M. Kurzay¹, R. Klaus¹, M. Geiger², F. Rataj¹, B. Cadilha¹, J. Keyl¹, S. Lesch¹, C. Heise¹, R. Murr², J. vom Berg³, M. Jastroch⁴, D. Lamp⁴, G. Niederfellner⁵, C. Sustmann⁵, S. Endres¹, C. Klein², S. Kobold¹; ¹Division of Clinical Pharmacology, LMU, Munich, Germany, ²Roche Innovation Centre Zurich, Schlieren, Switzerland, ³Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland, ⁴Helmholtz Diabetes Center and German Diabetes Center (DZD), Helmholtz Zentrum München, Munich, Germany, ⁵Roche Innovation Centre, Penzberg, Germany.

P07.03 Cytokine-Induced Killer cells combined with anti EGFR monoclonal antibody abrogate triple negative breast cancer metastatization

R. Sommaggio¹, E. Cappuzzello¹, A. Rosato^{1,2};
¹Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy, Padua, Italy, ²Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, Padua, Italy.

P07.04 Depletion of MDSC improves the anti-neuroblastoma effect of adoptive recipient leukocyte infusion in allogeneic bone marrow transplanted mice.

I. Dierckx de Casterlé¹, O. Rutgeerts¹, S. Fevery¹, S. Van Gool², M. Waer¹, A. D. Billiau¹, B. Sprangers³; ¹KU Leuven, Leuven, Belgium, ²Immunologisches Onkologisches Zentrum Köln, Köln, Germany, ³KU Leuven ; University Hospitals Leuven, Leuven, Belgium.

P07.05 Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells

S. J. Jacobi¹, F. Rataj¹, F. Asang¹, S. Stoiber¹, M. Benmebarek¹, R. Klaus¹, S. Endres¹, C. Klein², S. Kobold¹; ¹Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Munich, Germany, ²Roche Innovation Center Zurich, Schlieren, Switzerland.

POSTER SESSION P08.

Monitoring of immunotherapy

P08.02 CD73 activity and outcome of advanced melanoma patients treated with nivolumab

S. Morello¹, C. Sorrentino², M. Capone³, D. Giannarelli⁴, G. Madonna³, D. Mallardo³, A. M. Grimaldi³, A. Pinto¹, P. A. Ascierto³; ¹Department of Pharmacy, University of Salerno,, Salerno, Italy, ²Department of Pharmacy, University of Salerno, PhD Program in Drug Discovery and Development, Salerno, Italy, ³Melanoma, Cancer Immunotherapy and Innovative Therapies O.U., National Cancer Institute "G. Pascale", Naples, Italy, ⁴Regina Elena National Cancer Institute, Rome, Italy.

P08.04 Positive controls for cytometric in vitro T cell activation test for bladder carcinoma patient stratification and monitoring

P. Hadlova, A. Koladiya, K. Drbal; Charles University, Praha, Czech Republic.

POSTER SESSION P09.

Young Researcher Session

P09.01 Trends in incidence of head and neck cancers in India

D. Francis; Tagore dental College and Hospital, Chennai, India.

P09.02 Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives

E. Cappuzzello¹, R. Sommaggio¹, C. Kellner², M. Peipp², A. Rosato^{1,3}; ¹Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy, ²Division of Stem Cell Transplantation and Immunotherapy, ^{2°} Department of Medicine, Christian-Albrechts-University, Kiel, Germany, ³Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

P09.03 Exploring phenotypic and functional characteristics of cultured tumor infiltrating lymphocytes

M. Rana¹, T. Borch^{1,2}, A. Draghi¹, A. Gokuldass¹, M. Donia^{1,2}, I. Svane^{1,2}; ¹Center for Cancer Immune therapy (CCIT), Copenhagen, Denmark, ²Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark, Copenhagen, Denmark.

P09.04 A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors

J. Medina, M. Hinterberger, M. Testori, M. Geiger, R. Giessel, B. Bathke, R. Kassub, F. Graebnitz, G. Fiore, P. Chaplin, H. Hochrein, H. Lauterbach; Bavarian Nordic GmbH, Planegg, Germany.

P09.05 Expression of CD73 on MDSCs and CD8+/PD-1+ cells as new possible biomarkers for advanced melanoma patients treated with nivolumab

F. Fratangelo¹, S. Morello², G. Madonna¹, M. Capone¹, D. Mallardo¹, R. Falcone¹, A. M. Grimaldi¹, E. Simeone¹, V. Vanella¹, D. Giannarelli³, C. Sorrentino², A. Pinto², P. A. Ascierto¹; ¹S.C. Oncologia Clinica Sperimentale Melanoma Immunoterapia e Terapie Innovative - IRCCS - Fondazione G. Pascale, Naples, Italy, ²Dipartimento di Farmacia, Università di Salerno, Fisciano, Italy, ³Istituto Nazionale Tumori Regina Elena, Rome, Italy.

P09.06 M1 polarization of tumor-associated macrophages after irradiation of human rectal cancer in patients and 3D co-culture model


V. Stary¹, J. Strobl², A. Beer³, H. Dolznig⁴, M. Bergmann¹; ¹Department of Surgery, Medical University of Vienna, Vienna, Austria, ²Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria, ³Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, ⁴Institute of Genetics, Medical University of Vienna, Vienna, Austria.



FLOORPLAN

STAND NUMBER EXHIBITOR

- 1** Immudex
- 2** CleanNA
- 3** Bio-Techne
- 4** PerkinElmer
- 5** MBL International
- 6** 10X Genomics
- 9** Thermo Fisher Scientific
- 10** Bristol-Myers Squibb
- 11** The Cancer Drug Development Forum (CDDF)
- 12** NanoString Technologies
- 15** Meso Scale Discovery
- 16** ProQinase
- 17** Free Literature
- 18** NewLink Genetics
- 19** Agilent
- 20** The Society for Immunotherapy of Cancer (SITC)
- 21** Incyte



ACKNOWLEDGMENTS

GRANT DONATORS | SPONSORS | EXHIBITORS | PARTNERS

For questions regarding sponsorship and exhibition, please contact Rose International.



- Contact: Flora van Laer
- E-mail: fvanlaer@rose-international.com
- Telephone: +31 70 383 89 01

We thank all ITOC 5 grant donators, sponsors and partners.

The ITOC5 Organising Committee wishes to gratefully acknowledge our sponsors and exhibitors for supporting the 5th Immunotherapy of Cancer Conference (ITOC5).

GRANT DONATORS



Gilead Sciences Europe Ltd

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

→ View more at www.gilead.com



Merck Sharp & Dohme Corp.

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world.

→ For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

SPONSORS



F. Hoffmann-La Roche Ltd

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

→ View more at: www.roche.com



Incyte Corporation

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.

→ View more at www.incyte.com, and follow @Incyte on Twitter at <https://twitter.com/Incyte>



NanoString Technologies

NanoString is a life sciences company focused on cancer research and diagnostics. Proven in over 1,000 peer-reviewed publications, the nCounter® System can combine with 3D biology™ technology to create novel biomarkers. The Prosigna® Breast Cancer Prognostic Gene Signature Assay provides FDA 510(k)-cleared diagnostics with the nCounter Dx Analysis System.

→ View more at <https://www.nanostring.com/>



Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

→ For more information, please visit www.thermofisher.com

EXHIBITORS



10x Genomics

10x Genomics' Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information, including phased structural variants, phased single nucleotide variants, Single Cell gene expression and paired full length V(D)J repertoires —while leveraging their existing sequencing systems and workflows.

→ View more at <https://www.10xgenomics.com/>



Agilent Technologies

Agilent is a leader in life science research tools, providing analytical instruments, software, consumables and services for research laboratories worldwide. Agilent products including Seahorse, iLab, Dako, SureSelect, and mass spec are used in phenotyping, metabolomics, cell metabolism, and mitochondrial toxicity assays; as well as immunotherapy, cancer, and metabolic disease research.

→ View more at <https://www.agilent.com/en-us/promotions/seahorse-xf-technology>



Bio-Techne

Bio-Techne brings together some of the most referenced brands in life science – R&D Systems, Novus Biologicals, Tocris Bioscience, and ProteinSimple providing innovative, high-quality research tools. Together we are Bio-Techne. Find out how we can be your partner and help you attain your research goals by visiting our stand.

→ View more at www.bio-techne.com.



Bristol-Myers Squibb GmbH & Co. KGaA

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines. We are committed to Immuno-Oncology (I-O), a rapidly evolving field that enlists the immune system in the fight against cancer. As we learn more about how cancer evades the immune system, the growing potential of I-O drives our research efforts.

→ View more at <https://www.bms.com/>



The Cancer Drug Development Forum (CDDF)

CDDF looks forward to welcoming you at the 5th edition of the Immunotherapy of Cancer Conference (ITOC5) in Berlin. We will be available to meet you at the exhibition area, feel free to come and visit us at any time! The (CDDF) is an international organization providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.

→ View more on <http://cddf.org>



CleanNA

CleanNA's focuses on supplying an evolving market with high quality products, providing the latest technology, high-efficiency and cost-effective magnetic bead-based kits for both DNA and RNA isolation from various sample sources, for example Whole Blood, FFPE, Plant tissue, etc. A dedicated team combines both scientific and technical knowledge providing an ideal interface between the user and life science application(s).

→ View more at <http://www.cleanna.com/>



Immudex

Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

→ View more at www.immudex.com



Incyte Corporation

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.

→ View more at www.incyte.com, and follow @Incyte on Twitter at <https://twitter.com/Incyte>



MBL International

MBL International is a life science company focused on providing high quality, innovative, solutions-based products for life science research and clinical diagnostics. MBLI develops and manufactures a broad portfolio of monoclonal and polyclonal antibodies, MHC tetramers, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.

→ View more at <https://www.mblintl.com/>



Meso Scale Discovery

Meso Scale Discovery (MSD®) is a leader in high performance, multiplex-enabled biomarker assays for cytokines, toxicology, neurodegeneration and metabolic disease research, used by leading biopharmaceutical and academic researchers in human and animal model studies. MSD's proprietary electrochemiluminescence (ECL) platform delivers exceptional sensitivity, wide dynamic range and rapid turnaround.

→ View more at: www.mesoscale.com



NanoString Technologies

NanoString is a life sciences company focused on cancer research and diagnostics. Proven in over 1,000 peer-reviewed publications, the nCounter® System can combine with 3D biology™ technology to create novel biomarkers. The Prosigna® Breast Cancer Prognostic Gene Signature Assay provides FDA 510(k)-cleared diagnostics with the nCounter Dx Analysis System.

→ View more at <https://www.nanostring.com/>



NewLink Genetics

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.

→ View more at: www.newlinkgenetics.com



PerkinElmer

PerkinElmer is a global leader focused on improving human and environmental health, for the better. To accelerate the understanding of human health, we provide our customers with the knowledge, expertise and solutions to better diagnose, treat and prevent disease. Our full Phenoptics™ Research Solution, including Opal™ multiplexed staining reagents, multispectral imaging instrumentation (Vectra® Polaris™, Vectra® and Mantra™ Systems), and inForm® advanced image analysis software, enable immuno-oncology researchers to better understand the complex biology of the tumor microenvironment.

→ View more at www.perkinelmer.com/Phenoptics



ProQinase

ProQinase is a leading CRO for anti-cancer drug discovery providing customized solutions from biochemical and cellular testing to in vivo proof of concept. Apart from single service solutions, ProQinase also carries out integrated drug discovery projects as a "one-stop shop" solution provider. A main focus of ProQinase's expertise is a versatile immuno-oncology platform including syngeneic mouse models (subcutaneous, orthotopic, metastasis) and supporting immunoassays.

→ View more at www.proqinase.com



Society for Immunotherapy of Cancer

The Society for Immunotherapy of Cancer (SITC)

SITC is a 501 (c)(3) non-profit professional society of over 1,600 influential scientists and practitioners from around the world who are dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through emphasis on high-caliber scientific meetings, education, and collaborations, SITC brings together all aspects of cancer immunology and immunotherapy.

→ View more on www.sitcancer.org; <https://twitter.com/sitcancer>



Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

→ For more information, please visit www.thermofisher.com

PARTNERS



Society for Immunotherapy of Cancer



THE HOT TOPIC INTERACTIVE EXPERTS' SESSION ON
"COMBINATIONS TO TARGET IMMUNE EXCLUDED AND IMMUNE DESERT SOLID TUMOURS"
IS SUPPORTED BY A MEDICAL EDUCATION GRANT FROM:



SYMPOSIUM AGENDA

Tuesday, March 20, 2018 at 14.00 - 15.00hrs

Combinations to target immune excluded and immune desert solid Tumours

Chair: Rudolf Maria Huber

Introduction: NSCLC immune-phenotypes

Rudolf Maria Huber, Munich, Germany

Chemotherapy + checkpoint inhibitors and antiangiogenesis agent: rationale and emerging data

Solange Peters, Lausanne, Switzerland

Checkpoint inhibitor + T cell bispecific: rationale and emerging data

Ignacio Melero, Navarra, Spain

The Hot Topic Interactive Experts' Session is a new addition to ITOC5 program and aims to encourage an interactive and alternative debate, aiming to educate and engage participants. It will provide delegates attending with a further opportunity to question and exchange with experts in immunotherapy in a concise and interactive format. The session offers a privileged opportunity to interact with, and receive high-level guidance from, experts in the field. The Hot Topic Interactive Experts' Session is open to all ITOC5 participants.

GENERAL INFORMATION

SECRETARIATS

SECRETARIAT

The Cancer Drug Development Forum (CDDF)

Avenue E. Mounier 83, 1200 Brussels, Belgium

Phone: +32 (0)2 775 02 15

Email: cddf@ecco-org.eu

Website: www.cddf.org



CONFERENCE MATTERS

Vienna Medical Academy

Conference & Society Management

Contact: Catherine Tomek

E-mail: itoc@medacad.org

Telephone: +43 1 405 13 83 18

Website: www.medacad.org



SPONSORSHIP AND EXHIBITION MATTERS

Rose International

Exhibition Management & Congress Consultancy bv

Contact: Flora van Laer

E-mail: fvanlaer@rose-international.com

Telephone: +31 70 383 8901



CONFERENCE VENUE

Mercure Hotel Moa Berlin

Stephanstraße 41

Entrance through Shoppingcenter at Birkenstraße 23, 1st Floor

10559 Berlin, Germany

Telephone: +49 (0) 30 39 40 43 158



HOW TO REACH THE VENUE

- **By car:** Address : Birkenstraße 23
550 parking spaces in the shopping center "MOA Bogen"
Direct access to the hotel on the 2nd floor P4 (level 4)
- **By Metro:** Station U9 Birkenstrasse
- **By Bus:** Station 123 Stendaler Strasse



REGISTRATION

Registration Hours

- Monday, March 19, 2018 _____ 09:00 - 18:30 hrs
- Tuesday, March 20, 2018 _____ 07:30 - 18:30 hrs
- Wednesday, March 21, 2018 _____ 08:00 - 13:30 hrs

Registration fees in Euro

Payment received:	Early Bird until Dec. 15, 2017	From December 16 to March 9, 2018	On-Site
Academia	450,-	550,-	650,-
Junior Participant ¹	120,-	150,-	175,-
Industry	750,-	850,-	950,-
SITC Members – Academia ²	380,-	480,-	580,-
SITC Member – Junior Participant ²	100,-	130,-	155,-
Foundations & Charities	225,-	275,-	325,-
Press/Media Pass Registration ³	No fee, but registration is mandatory		
Welcome Reception	No fee, but registration is mandatory		
Conference Dinner for registered participants	75,-		

¹ The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration.

² Please provide the SITC Promotional Code during on site registration. Note: the reduced registration fee only applies if the code is provided – make sure to inquire with SITC prior to your on site registration.

³ A Press ID confirming your status must be provided at the moment of your registration.

IMPORTANT:

Reduced registration fees are only applicable, if they have been credited to the congress account before the respective deadlines. Registering before a deadline without performing an actual payment was not sufficient to benefit from the reduction. Please note that a different fee applies for onsite payments and registrations. **If the fee is not transferred to the congress bank account before the respective deadline expires the fee will be changed to the next applicable fee automatically.**

What is covered by the registration fee?

- Admission to all scientific sessions
- Abstract book and programme
- Welcome reception (no fee but registration mandatory)
- Coffee breaks & Lunches
- Admission to exhibition

Cancellations

Please note that only written cancellations addressed to ITOC5 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:

- before January 31, 2018: 50% refund
- after January 31, 2018: no refund

Replacements

Any replacement (i.e. change of delegate name) of a confirmed registration is subject to a 50 EUR charge per participant.

BADGES

For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

CATERING

Coffee breaks, lunches and a welcome reception have been scheduled. Exact times are listed in the programme overview.

CERTIFICATE OF ATTENDANCE

The 5th ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference. It is possible to claim a maximum of 15 CME points for attendance of scientific sessions at the ITOC5.

EXHIBITION

The exhibition is held in the "Atrium" of the Mercure Hotel MOA Berlin. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

INSURANCE

By registering to the ITOC5 participants agree that neither the organising committee nor the congress office assume any liability whatsoever.

Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

LANGUAGE & TRANSLATION

The official language of the conference is English. No simultaneous translation is provided.

LOST & FOUND

All enquiries should be directed to the registration desk situated on 1st Floor. The organizers accept no responsibility for loss due to theft or negligence.



NETWORKING EVENTS

Monday, March 19, 2018

Welcome Cocktail in the exhibition area of the venue Hotel Mercure MOA

No fee for registered participants, but registration is mandatory!

Tuesday, March 20, 2018

Conference Dinner

Altes Zollhaus

Carl-Herz-Ufer 30

10961 Berlin

www.altes-zollhaus-berlin.de

Time: 20.00 hrs

Bus departure from the venue Hotel Mercure MOA at 19.40 hrs

Contribution towards expenses: EUR 75,-



POLICIES

ITOC5 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC5 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.



Society for Immunotherapy of Cancer

Advancing the Science and Application of Cancer Immunotherapy

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC has more than 1,900 members representing 17 medical specialties in 38 countries, serving scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders. Through education programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

Among others, SITC resources include:

Discounted
rate for SITC
members

- **SITC 2018 Annual Meeting & Pre-Conference Programs**

- November 7-11, 2018 in Washington DC

- ***Journal for ImmunoTherapy of Cancer (JITC)***

- SITC's international, open access, peer-reviewed journal
- Article processing charges are waived for SITC members through 2018 (a \$2,500 value)

Discounted
rate for SITC
members

- **Upcoming Interim Workshops Focusing on Critical Next Steps in the Field**

- May 14-15, 2018: Cancer Immune Responsiveness Workshop (San Francisco, Calif.)
- May 16-17, 2018: Immuno-Oncology Biomarkers: State of the Art (San Francisco, Calif.)

- **SITC CONNECT Website (sitcancer.org)**

- SITC's hub for the latest news, research and community conversation related to cancer immunotherapy
- **connectED:** SITC's continuously growing selection of CE-certified cancer immunotherapy courses, presentation materials from past SITC events and more in this free online education portal

Learn more at **sitcancer.org**

transforming healthcare **FROM INSIGHT TO IMPACT**

VISIT US AT BOOTH 12 AND DISCOVER:

- 3D Biology™ Technology for multi-analyte studies
- Digital Spatial Profiling Technology
- NanoString poster #P02.06: Digital spatial profiling platform allows for spatially- resolved, multiplexed measurement of solid tumor protein distribution and abundance in FFPE tissue sections.

LEARN MORE AT [NANOSTRING.COM](https://nanosttring.com)



nanoString
TM

© 2018 NanoString Technologies, Inc. All rights reserved.